Immix Biopharma, Inc. · NASDAQ:IMMX
Immix Biopharma — Investor Presentation (September 2026)
34 slides from Immix Biopharma's investor presentation, September 2026
Slide 1: Global Leader in Relapsed/Refractory AL Amyloidosis
Global Leader in Relapsed/Refractory AL Amyloidosis This presentation contains NEXICART-2 clinical data update on pages 19-24 September 2026
Slide 2: Disclaimer: Forward Looking Statements & Market Data
Disclaimer: Forward Looking Statements & Market Data This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immix Biopharma, Inc.
Slide 3: The moment every doctor and family dreads…
The moment every doctor and family dreads… “There’s nothing more we can do.” In AL amyloidosis, that sentence has been delivered to approximately 30,506 patients living in the U.S. today Source: 30,506 – prevalence = patients eligible for treatment with NXC-201 as of 2026 which excludes 1,271 mayo s
Slide 4: I've been the doctor in that room
I’ve been the doctor in that room. I’ve watched hope disappear. And I couldn’t accept that suffering was “standard of care.” Ilya Rachman, MD, PhD Chief Executive Officer, Founder
Slide 5: When your immune system becomes your killer
When your immune system becomes your killer One week of antibody production Mutations cause continuously produced antibodies clears a cold/flu like a superhero to flood organs with toxic light chains, transforming into supervillains ✓ X Source: Kyu S. et al. Frequencies of Human Influenza-specific A
Slide 6: The Toxic Last Ditch Effort
The Toxic Last Ditch Effort A single FDA approval – a 4-drug combination – exists, for newly diagnosed patients only. And it doesn’t work for everyone. Once relapse hits, there's nothing FDA approved. Then, doctors resort to off-label drug use, despite their limited efficacy Note: ~2/3 of patients a
Slide 7: AL Amyloidosis Response Rate After The 4-Drug Combination Fails
AL Amyloidosis Response Rate After The 4-Drug Combination Fails 12 PATIENT SERIES RELAPSED/REFRACTORY AL AMYLOIDOSIS RECEIVING SECOND LINE THERAPY IN US 1 2 3 4 5 6 7 8 9 10 11 12 Patient 1 2 3 4 5 6 7 8 9 10 11 12 There are no drugs approved in relapsed/refractory AL amyloidosis. Disease burden Cur
Slide 8: AL Amyloidosis: 30,506 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs
AL Amyloidosis: 30,506 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs NXC-201 TARGETS PLASMA CELLS THAT CONTINUOUSLY PRODUCE TOXIC LIGHT CHAINS Light chains deposit in organs, damaging organs Light chains produced by Light chains misfold and dysfunctional plasma cells aggregate Heart P
Slide 9: We're developing a breakthrough to change that hopeless sentence
We’re developing a breakthrough with the goal to change that hopeless sentence Our mission is simple: Create medicines that work without destroying the person.
Slide 10: The Science That Enables Our Platform
Ex-NCI/NIH Immix academic researchers ambitiously formulated a thesis: can The Science That Enables Our Platform cell therapy be expanded to a broader patient population, beyond cancer? Result: Sterically-optimized NXC-201 Impeded phosphorylation of ITAM1, added ubiquitination site… led to “digital”
Slide 11: Extraordinary Results in Clinical Trials
Extraordinary Results in Clinical Trials Relapsed/refractory AL Amyloidosis - Market Situation Current Standards of Care NXC-201 0-10% complete response rate 89% complete response rate, (standard of care) potentially increasing to 98% (NEXICART-2 45 patients) Note: R/R AL current standard of care th
Slide 12: What that can mean for the patient…
What that can mean for the patient… Life becomes normal again. A deep breath that reaches the bottom of the lungs. A walk that doesn't end at the mailbox. A normal heartbeat again. 12
Slide 13: The Multi-Billion Dollar Opportunity
The Multi-Billion Dollar Opportunity Prevalence Incidence AL Amyloidosis Overall Survival Existing therapies 30,506 • ~35% of Era 4 (2010-2019) patients on 5,386 Darzalex Era 3 (2000-2009) patients … Of combos ~80% eligible for × Darzalex Subtract 4% which, reach a CR treatment Cardiac stage 5.9 yea
Slide 14: The Road Ahead
The Road Ahead Prior 2Q25 3Q25 4Q25 1Q26 Q3 26 1H 27 ✓ Secured rights to NXC-201, N-GENIUS platform from ex- U.S. university ✓ Reported ex-U.S. NEXICART-1 AL Amyloidosis data at ASGCT 2023, ASH 2023, ASGCT 2024, ASH 2024, JCO published 2024 ✓ FDA Orphan Drug Designation (ODD) and Regenerative Medici
Slide 15: Commercial
Commercial 20 high-prescribing Sites in existing Immix clinical trial Commercial launch plan end of 20271 AL Amyloidosis annual sales: ~$2.1bn2 1. Assuming BLA submission 1H 2027 and subsequent BLA approval 2. (5,386 new cases AL) / (SEER New Cases MM in 2025 36,110) = 14.9% * $14bn annual run rate
Slide 16: A World Class Team Dedicated To Saving Lives
A World Class Team Dedicated To Saving Lives Ilya Rachman, MD, PhD David Marks, MBBS, PhD Chief Executive Officer Chief Medical Officer Amanda Squires Gabriel Morris Head of Clinical President, Chief Financial Officer Operations Michael Grabow Oleg Evgrafov, Chief Commercial Officer Head of Quality
Slide 17: We believe we are on the brink of turning despair into hope
We believe we are on the brink of turning despair into hope Success here opens the door to treating other serious diseases 17
Slide 18: NEXICART-2 U.S. Relapsed/Refractory AL Amyloidosis Trial (NCT06097832)
NEXICART-2 U.S. Relapsed/Refractory AL Amyloidosis Trial (NCT06097832) U.S. TRIAL WITH REGISTRATIONAL DESIGN, ENROLLMENT COMPLETED Study design • Open-label, single-arm, multi-site phase 1/2 study • n=45 patients Key criteria •AL Amyloidosis patients exposed to at least 1 line of therapy including a
Slide 19: NEXICART-2 (U.S.) Baseline Characteristics
NEXICART-2 clinical data NEXICART-2 (U.S.) Baseline Characteristics: Representative of U.S. R/R AL Amyloidosis Patient Population 150 450 CART Cell Dose (x106) (n=3) (n=42) Age, median years (range) 67 (56-82) 65 (47-82) Sex, female (%) 2 (67%) 18 (43%) Number of prior lines of therapy, median (rang
Slide 20: NEXICART-2 (U.S.) Efficacy: Rapid Normalization of Diseased Light Chains
NEXICART-2 clinical data NEXICART-2 (U.S.) Efficacy: Rapid Normalization of Diseased Light Chains within ~First Week 300 2 300 Disease Burden dFLC Percentage Decline by Day (Best Response) at NXC-201 250 M-spike Dosing: 0% (g/dL) dFLC (mg/L) 200 150 1 -20% 100 50 0 0 -40% Patient NX2- 0% 1 2 4 5 6 7
Slide 21: NEXICART-2 (U.S.) Clinical Activity: 89% Complete Responses
NEXICART-2 clinical data NEXICART-2 (U.S.) Clinical Activity: 89% Complete Responses (CR) – 40/45 Patients MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 98% Patients: NX2- 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Slide 22: Deep, Rapid, Sustained Organ Responses Observed to date in NEXICART-2
NEXICART-2 clinical data Deep, Rapid, Sustained Organ Responses Observed to date in NEXICART-2 Representative Sequence of Events for NEXICART-2 Median day 7: toxic light chains normalize “In all organs, the deeper the organ response achieved, the longer the survival.” Day 25 : MRD negativity – Eli M
Slide 23: NEXICART-2 (U.S.) TEAE Summary
NEXICART-2 clinical data NEXICART-2 (U.S.) TEAE Summary • No patient experienced a Grade 5 TEAE across any cohort related to NXC-201 150 450 CART Cell Dose (x106) (n=3) (n=42) Grade Any Grade Grade >3 Any Grade Grade >3 Any TEAE, n (%) 3 (100%) 3 (100%) 45 (100%) 36 (92%) n (%) 1 (33%) 0 37 (88%) 0
Slide 24: Complete Response Rate Improving Over Time
Complete Response Rate Improving Over Time Data Cutoff: April 11, 2025 November 13, 2025 May 14, 2026 August 4, 2026 with May 2026 update 89% MRD negativity in bone marrow CR RATE: 70% 75% 95% predicts future complete response, potentially increasing future CR rate up to 98% Subject # NX2- Subject #
Slide 25: NEXICART-3 U.S. Newly Diagnosed AL Amyloidosis Trial (NCT07709715)
NEXICART-3 U.S. Newly Diagnosed AL Amyloidosis Trial (NCT07709715) PHASE 3 RANDOMIZED CONTROLLED TRIAL –INITIATION PLANNED FOR 1H 2027 Study design • Randomized 1:1, multi-site phase 3 study • Arm A: NXC-201 • Arm B: DaraCyBorD Key criteria Inclusion •Newly diagnosed AL Amyloidosis patients •Cardiac
Slide 26: Global Leader in relapsed/refractory AL Amyloidosis
Global Leader in relapsed/refractory AL Amyloidosis September 2026
Slide 27: NXC-201 Tolerability Drives AL Amyloidosis Leadership
NXC-201 Tolerability Drives AL Amyloidosis Leadership ALL BCMA CAR-TS ARE NOT CREATED EQUAL Median CRS Duration (Days) NXC-201’s short CRS duration, if proven to be safe and NXC-201 effective, makes it uniquely suitable to treat ALA Anito-cel D8 BCMA KLN-1010 /CARTddBCMA /AUTO8 patients (in whom the
Slide 28: NXC-201: Deepest Responses, In Most Heavily Pretreated Population
NXC-201: 1 Deepest Responses, 2 In Most Heavily Pretreated Population NXC-201 Etentamig Linvoseltamab Teclistamab NXC-201: n 45 34 20 52 Later Phase … Phase Phase 2 Phase 1 Phase 2 Retrospective Dosing Frequency 1-Time 24 Months (QW4) Weekly 8W, QW4 40W Monthly Median Prior Lines 3 2 1 2 … in heavil
Slide 29: Market Reference: Commercialization Cost Trend Over Time
Market Reference: Commercialization Cost Trend Over Time $1,200 Yescarta 2017 ~$1bn Gilead highlighted cell therapy business was close to $1,000 break-even in 2024, with sales ~$1.5bn $800 Elevidys COGS + SG&A(1) in Launch Year 2023 $600 $544 (3) (2) $528 $479 Casgevy 2023 Carvykti $400 New launches
Slide 30: NEXICART-1 (Israel): Normalization of Toxic Free Light Chains 30 Days after Dosing
NEXICART-1 (Israel): Normalization of Toxic Free Light Chains 30 Days after Dosing BACKGROUND: IMMIX LICENSED-IN NXC-201 BASED ON EX-U.S. DATA SHOWING PLASMA CELL ELIMINATION IN RELAPSED/REFRACTORY AL AMYLOIDOSIS(MENTIONED IN NEJM) Patient 1 2 3 4 5 9 10 12 13 14 15 16 6 7 8 11 300 Disease Burden Pr
Slide 31: Up to 91% of Frontline Patients Require 2nd Line Therapy within 12 Months
Up to 91% (=18+64+9) of AL Amyloidosis Patients Receiving Frontline Dara-Cy-Bor-D Require 2nd Line Therapy within 12 Months based on peer studies 100 newly diagnosed 18 don’t reach 82 reach (1) 6 cycles 6 cycles(1) (2) 18 (22%) 64 (78%) reach CR(2) don’t reach CR (2) 9 (50%) relapse <12M(2) Note: Ex
Slide 32: 100% of doses manufactured successfully, median vein-to-vein time of 14 days
100% of doses manufactured successfully, median vein-to-vein time of 14 days 45 44 43 42 41 40 39 38 37 36 35 34 33 32 31 30 29 28 27 26 25 24 23 Patient 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 2 4 6 8 10 12 14 16 Days Notes: Source: Based on Company internal metrics. 32
Slide 33: AL Amyloidosis Diagnoses Have Increased, Driven by Awareness and ATTR Diagnosis
AL Amyloidosis Diagnoses Have Increased, Driven by Awareness and ATTR Diagnosis Steps Every ATTR Diagnosis Requires AL Light Chain Test (to Rule Out AL Amyloidosis) US AL Diagnoses are Trending Up, Paralleling ATTR2 1 Amyloidosis (both ATTR and AL) present as heart failure 2 Distinct diagnosed patie
Slide 34: Global Leader in Relapsed/Refractory AL Amyloidosis
Global Leader in Relapsed/Refractory AL Amyloidosis This presentation contains NEXICART- 2 clinical data update on pages 19-24 September 2026
Immix Biopharma — Investor Presentation (September 2026) on 6ix